HC Wainwright & Co. maintains $12.00 share target for Protalix BioTherapeutics
HC Wainwright & Co. maintained a $12.00-per-share price target for Protalix BioTherapeutics, per Benzinga ratings actions.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.